Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ciclesonide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | ciclesonide 50 and 200ug |
| 2 | ACTIVE_COMPARATOR | ciclesonide 100ug and 400ug |
| Name | Type | Description |
|---|---|---|
| ciclesonide | DRUG | low dose- 50ug and 200ug |
Inclusion Criteria: * stable asthma not on maintenance asthma medications * exercise induced bronchoconstriction on dry air exercise challenge. Exclusion Criteria: * other significant co-morbidity or treatments that might interfere with the conduct or results of the study * fail to return to base...
Ciclesonide is used for asthma. It is a small molecule being developed by Takeda Pharmaceutical Company Limited for the treatment of asthma, a respiratory condition. The drug is currently in Phase 3 clinical development for this indication.
Ciclesonide is a small molecule developed for asthma. The specific molecular target of ciclesonide is not disclosed in the available information. It is being studied for its effects on exercise-induced bronchoconstriction in patients with asthma.
Ciclesonide is being developed by Takeda Pharmaceutical Company Limited, a company listed on the stock exchange under the ticker TAK. Takeda is conducting clinical trials to evaluate the drug for the treatment of asthma.
Ciclesonide is in Phase 3 clinical development for asthma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in a completed Phase 3 trial to assess its efficacy and safety.
Ciclesonide has one completed Phase 3 clinical trial with the identifier NCT00525772, titled 'Effect of Ciclesonide on Exercise Induced Bronchoconstriction'. This trial enrolled 26 participants with asthma in Canada, was randomized, double-blind, and active-controlled, and included patients aged 12 years and older.
Ciclesonide is not known to have alternative names. It is a distinct small molecule being developed by Takeda for asthma. No other names for this drug have been reported in the available clinical trial information.